Rapid weight loss itself carries theoretical thrombotic risk only in specific populationsthose with pre-existing clotting disorders or prolonged immobility
These effects are rare and typically resolved with dose adjustment
Some studies have employed mass spectrometry (MS) to analyze differences in lipid metabolites between ARDS patients and healthy individuals
To enroll, one of the following must apply: BMI 27 and an obesity-related comorbid condition BMI 30 with or without comorbid condition Obesity-related comorbid conditions include but are not limited to diabetes, prediabetes, hypertension, dyslipidemia, CAD, osteoarthritis, and obstructive sleep apnea
Enhanced leptin reduction leads to further reduction in hepatic steatosis and fibrosis
However, they will not disappear from the market when AAS are still used